- Home
- LEGH vs AUTL Comparison
LEGH vs AUTL Comparison
Compare LEGH & AUTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LEGH
- AUTL
- Stock Information
- Founded
- LEGH 2005
- AUTL 2014
- Country
- LEGH United States
- AUTL United Kingdom
- Employees
- LEGH N/A
- AUTL N/A
- Industry
- LEGH Homebuilding
- AUTL Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- LEGH Consumer Discretionary
- AUTL Health Care
- Exchange
- LEGH Nasdaq
- AUTL Nasdaq
- Market Cap
- LEGH 588.8M
- AUTL 625.4M
- IPO Year
- LEGH 2018
- AUTL 2018
- Fundamental
- Price
- LEGH $23.97
- AUTL $2.37
- Analyst Decision
- LEGH Strong Buy
- AUTL Strong Buy
- Analyst Count
- LEGH 2
- AUTL 5
- Target Price
- LEGH $29.00
- AUTL $9.32
- AVG Volume (30 Days)
- LEGH 102.9K
- AUTL 2.1M
- Earning Date
- LEGH 08-07-2025
- AUTL 08-07-2025
- Dividend Yield
- LEGH N/A
- AUTL N/A
- EPS Growth
- LEGH 8.04
- AUTL N/A
- EPS
- LEGH 2.29
- AUTL N/A
- Revenue
- LEGH $176,618,000.00
- AUTL $9,011,000.00
- Revenue This Year
- LEGH N/A
- AUTL $461.76
- Revenue Next Year
- LEGH $8.23
- AUTL $112.66
- P/E Ratio
- LEGH $10.47
- AUTL N/A
- Revenue Growth
- LEGH N/A
- AUTL N/A
- 52 Week Low
- LEGH $21.58
- AUTL $1.11
- 52 Week High
- LEGH $29.31
- AUTL $5.00
- Technical
- Relative Strength Index (RSI)
- LEGH 63.30
- AUTL 70.63
- Support Level
- LEGH $21.91
- AUTL $2.20
- Resistance Level
- LEGH $24.17
- AUTL $2.44
- Average True Range (ATR)
- LEGH 0.61
- AUTL 0.12
- MACD
- LEGH 0.27
- AUTL -0.01
- Stochastic Oscillator
- LEGH 89.96
- AUTL 84.95
About LEGH Legacy Housing Corporation (TX)
Legacy Housing Corp builds, sell, and finance manufactured homes and tiny houses that are distributed through a network of independent retailers and company-owned stores and also sold directly to manufactured home communities. The company also provides financing options to its customers to facilitate the sale of homes.
About AUTL Autolus Therapeutics plc
Autolus Therapeutics PLC is a biopharmaceutical company developing next-generation programmed T-cell therapies for the treatment of cancer. The company's clinical-stage pipeline comprises Obe-cel (obecabtagene autoleucel), AUTO1/22, AUTO3, AUTO5, AUTO6, AUTO7 & AUTO8.